Phibro Animal Health (PAHC) Projected to Post Quarterly Earnings on Wednesday

Phibro Animal Health (NASDAQ:PAHC) is expected to be posting its Q4 2026 results after the market closes on Wednesday, August 26th. Analysts expect the company to announce earnings of $0.7130 per share and revenue of $381.1760 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2026 earning report for the latest details on the call scheduled for Thursday, August 27, 2026 at 9:00 AM ET.

Phibro Animal Health Trading Down 2.8%

NASDAQ PAHC opened at $35.31 on Tuesday. The firm has a market capitalization of $1.43 billion, a PE ratio of 15.15, a price-to-earnings-growth ratio of 0.51 and a beta of 0.46. The business’s 50-day moving average price is $33.76 and its two-hundred day moving average price is $42.57. The company has a current ratio of 3.17, a quick ratio of 1.26 and a debt-to-equity ratio of 1.97. Phibro Animal Health has a 12 month low of $28.25 and a 12 month high of $60.08.

Phibro Animal Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 23rd. Investors of record on Wednesday, September 2nd will be paid a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date of this dividend is Wednesday, September 2nd. Phibro Animal Health’s payout ratio is currently 20.60%.

Institutional Investors Weigh In On Phibro Animal Health

Hedge funds and other institutional investors have recently bought and sold shares of the stock. iSAM Funds UK Ltd bought a new position in shares of Phibro Animal Health during the 3rd quarter worth about $61,000. EverSource Wealth Advisors LLC increased its position in Phibro Animal Health by 7,671.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company’s stock valued at $69,000 after buying an additional 2,685 shares in the last quarter. C M Bidwell & Associates Ltd. raised its stake in Phibro Animal Health by 1,756.5% during the 4th quarter. C M Bidwell & Associates Ltd. now owns 2,135 shares of the company’s stock worth $80,000 after buying an additional 2,020 shares during the period. Advisory Services Network LLC acquired a new position in Phibro Animal Health during the 3rd quarter worth approximately $96,000. Finally, Tower Research Capital LLC TRC boosted its holdings in Phibro Animal Health by 768.2% in the second quarter. Tower Research Capital LLC TRC now owns 4,610 shares of the company’s stock worth $118,000 after acquiring an additional 4,079 shares in the last quarter. 99.34% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on PAHC. Weiss Ratings downgraded shares of Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, June 15th. Wall Street Zen downgraded shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Zacks Research lowered shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 21st. Finally, Citigroup decreased their price objective on shares of Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating for the company in a research report on Thursday, May 14th. One equities research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Phibro Animal Health presently has a consensus rating of “Hold” and an average target price of $42.50.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.